

## **Amendment to the claims**

This listing of claims will replace all prior versions, and listings, of claims in the application :

Claims 1 – 14. Cancelled

15. (New) A liposomal-based parenteral composition comprising:
  - (a) an aqueous phase comprising an aqueous buffer solution;
  - (b) a lipidic phase comprising single bilayered liposomes dispersed within the aqueous phase; and
  - (c) an effective amount of an active ingredient comprising erythropoietin or its pharmaceutically acceptable derivatives having the biological properties of causing bone marrow cells to increase production of reticulocytes and red blood cells, said active ingredient being dispersed within the aqueous phase and being substantially unincorporated within the liposomes.
16. (new) The composition of claim 15, wherein the single bilayered liposomes made by preparing a solution of the lipidic phase in an alcoholic solvent and injecting the solution under pressure into the aqueous buffer solution contained in a high speed homogenizer.
17. (new) The composition of claim 15, further comprising a stabilizer.
18. (new) The composition of claim 17, wherein the stabilizer is glycine.
19. (new) The composition of claim 15, wherein the aqueous buffer solution is an aqueous phosphate solution.
20. (new) The composition of claim 19, wherein said aqueous phosphate solution is selected from the group consisting of a sodium dihydrogen phosphate dihydrate solution, a di-sodium hydrogen phosphate dihydrate solution and mixtures thereof.
21. (new) The composition of claim 15, further comprising a preserving agent.
22. (new) The composition of claim 15, further comprising an antioxidant.
23. (new) The composition of claim 15, further comprising a complexing agent.